CytoMed Therapeutics (NASDAQ:GDTC) PT Set at $4.16 by Fundamental Research

CytoMed Therapeutics (NASDAQ:GDTC) has been assigned a $4.16 price objective by research analysts at Fundamental Research in a research report issued on Tuesday, BayStreet reports. The brokerage presently has a “buy” rating on the stock. Fundamental Research’s price objective suggests a potential upside of 418.06% from the stock’s previous close.

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of CytoMed Therapeutics in a research note on Wednesday, July 8th. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, CytoMed Therapeutics presently has a consensus rating of “Hold” and a consensus price target of $4.16.

CytoMed Therapeutics Stock Performance

GDTC stock traded down $0.05 during mid-day trading on Tuesday, hitting $0.80. 12,529 shares of the company were exchanged, compared to its average volume of 238,989. The business has a 50 day simple moving average of $0.91 and a 200-day simple moving average of $1.00. The company has a current ratio of 5.17, a quick ratio of 5.17 and a debt-to-equity ratio of 0.06. CytoMed Therapeutics has a 1-year low of $0.68 and a 1-year high of $3.68.

About CytoMed Therapeutics

CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. Its lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity. The company is also developing iPSC-gdNKT, a pluripotent stem cell-derived gamma delta natural killer T cells platform for cancer treatment; CTM-GDT, a product candidate that consists of expanded allogeneic gamma delta T cells and exploits the potential of the cells to recognize and treat a broad range of cancers; and CTM-MSC, an injectable allogeneic umbilical cord derived mesenchymal stem cells for cartilage injury.